Standout Papers

Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular... 2022 2026 2023 2024122
  1. Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma (2022)
    Pei‐Chang Lee, Ya‐Wen Hung et al. Journal for ImmunoTherapy of Cancer

Immediate Impact

58 standout
Sub-graph 1 of 23

Citing Papers

The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
2025 Standout
Gut microbiota-derived short-chain fatty acids and their role in human health and disease
2025 Standout
2 intermediate papers

Works of Ya‐Wen Hung being referenced

Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma
2022 Standout
Real-world experience of pembrolizumab plus lenvatinib in unresectable hepatocellular carcinoma in Taiwan.
2020

Author Peers

Author Last Decade Papers Cites
Ya‐Wen Hung 142 92 80 111 10 289
Shana White 60 60 50 101 8 253
Patrick Pham 47 52 120 68 13 271
F. Chapel 172 178 36 30 15 318
Junyan Feng 51 62 121 23 8 233
Amy Collinsworth 53 56 35 49 14 287
Lina Jiang 33 50 63 29 13 260
Peng Wang 17 40 58 66 19 228
Danielle E. Engler 19 65 97 65 11 332
Bernard Fischbach 48 47 148 19 16 301
Pavandeep Ghataorhe 20 35 76 16 9 326

All Works

Loading papers...

Rankless by CCL
2026